Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NQO1 | P15559 | 1/20 | 0.30 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL734304 | 0.81 | ABCG2 (0.32) | — | |
| SCHEMBL14028769 | 0.75 | CYP2A6 (0.38) | CYP2A6CYP1A2POLBCASP6TDP1 | |
| SCHEMBL11408529 | 0.71 | ALDH1A1 (0.38) | CYP1A2TDP1MAPT | |
| SCHEMBL3077123 | 0.70 | CYP1A2 (0.39) | CYP2A6CYP1A2POLBCASP6TDP1 | |
| SCHEMBL12230516 | 0.68 | POLB (0.36) | CYP2A6CYP1A2POLBCASP6TDP1 | |
| SCHEMBL406194 | 0.65 | POLB (0.47) | CYP2A6CYP1A2POLBCASP6TDP1 | |
| SCHEMBL903605 | 0.65 | AHR (0.46) | CYP2A6CYP1A2POLBCASP6TDP1 | |
| SCHEMBL16779994 | 0.65 | AHR (0.46) | CYP2A6CYP1A2POLBCASP6TDP1 | |
| Anthracene SCHEMBL6313219 | 0.64 | CYP2A6 (0.50) | CYP2A6CYP1A2TDP1MAPTNQO1 | |
| SCHEMBL22331573 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004404-A1 | RADIOLABELLING METHODS | HAMMERSMITH IMANET LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004404-A1 | RADIOLABELLING METHODS | ARFGEF1, TMEM14C, PIGO | CYP2A6 1489/4885CYP1A2 956/4885POLB 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.